Coats on for Starpharma
Tuesday, 09 September, 2008
Starpharma [ASX: SPL] has licensed the marketing rights to its VivaGel coated condom to SSL International, owners of the market-leading Durex condom brand.
Under the agreement, SSL has been granted the right to marketing the VivaGel condom in most of the world, including Europe and the US.
The agreement could be worth at least $100 million in royalties, milestone payments and development support to Starpharma.
Starpharma is continuing to develop VivaGel as an applicator-delivered vaginal product designed to help women protect themselves from HIV and genital herpes.
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...
Maternal cannabis use puts kids at risk of behavioural problems
Children exposed to their mother's cannabis use during pregnancy and after birth are three...
